1.
Cleve Clin J Med
; 84(6): 463-470, 2017 Jun.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28628428
RESUMEN
Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.